Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 248

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 6
Chunk 248
---
----------------------------------------------------------------------------------------------------------------------------

●   assessing the performance of the CEO and, in cooperation with the CEO, of other Executive Committee members and senior management.
--------------------------------------------------------------------------------------------------------------------------------------
Remuneration Committee
​
Our Remuneration Committee consists of three members (situation as of December 31, 2024): Elisabeth Svanberg (Chair), Jérôme Contamine, Dan Baker (member until June 18, 2024) and Simon Sturge (member as of June 18, 2024).
​
Our Board of Directors has determined that all members of our Remuneration Committee are Independent Non-Executive Board members.
​
Concerning our company’s Remuneration Policy, the Remuneration Committee’s duties and responsibilities to carry out its purposes include, among others, without any limitation:
​

●   making recommendations to the Board of Directors on the remuneration of our Board members, CEO and Executive Committee members, including, but not limited to, variable remuneration and long-term incentives, whether or not stock-related, in the form of subscription rights or other financial instruments;
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

●   establishing the Remuneration Policy and strategy for our Board members, Executive Committee members and senior management; and
-----------------------------------------------------------------------------------------------------------------------------------
​
177

●   preparing and submitting a remuneration report to the Board of Directors for inclusion in the annual report.
----------------------------------------------------------------------------------------------------------------
​
​
Science and Development Committee
​
Our Science and Development Committee, established on September 19, 2023, consists of four members (situation as of December 31, 2024): Dan Baker (Chair and member until October 6, 2024), Stoffels IMC BV (permanently represented by Dr. Paul Stoffels), Elisabeth Svanberg, Linda Higgins, and Susanne Schaffert (Chair as from October 28, 2024). 
​
The Science and Development Committee provides input and advice to the Board of Directors on matters relating to the Company’s Research and Development (“R&D”) strategy, and serves as a resource, as needed, regarding scientific, medical and product safety matters. 
​
Half of the members of the Science and Development Committee are Non-Executive Independent Directors. The Chair of the Science and Development Committee is a Non-Executive Independent Director. Collectively, the Science and Development Committee members have sufficient relevant experience to fulfill their roles effectively. 
​
​
Ad Hoc Committee
Our Ad Hoc Committee, established